Repeat use [Regulatives / Guidelines]

posted by Ohlbe – France, 2013-04-24 13:41 (4421 d 19:07 ago) – Posting: # 10486
Views: 14,551

Hi El Maestro,

❝ If there is any concern it has probably been caught by the pharmacovigilance system.


I doubt it, unless it is really a big, big problem... The substitution of the reference product by the generic is made by the pharmacist selling the drug to the patient. The prescriber usually doesn't even know which generic was given to his patient. If, by some sort of a miracle, he decides to make a pharmaco­vigilance declaration, to which product will he assign the AE ?

Sorry for being pessimistic, but I don't have much trust in the pharmaco­vigilance of generics :-(

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,678 registered users;
17 visitors (0 registered, 17 guests [including 15 identified bots]).
Forum time: 08:48 CEST (Europe/Vienna)

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5